Enliven Therapeutics increased its research and development spending in the fourth quarter of fiscal 2024 as several drug ...

The Board will present its formal recommendation regarding director nominees in the Company’s definitive proxy statement and other materials, to be filed with the Securities and Exchange Commission ...

Gogo boosted its year-over-year sales significantly in the fourth quarter of 2024 — a period in which Gogo acquired Satcom Direct — but posted a net loss.